IDYA
Price
$25.69
Change
+$0.02 (+0.08%)
Updated
Sep 25 closing price
Capitalization
2.25B
46 days until earnings call
NERV
Price
$2.17
Change
-$0.03 (-1.37%)
Updated
Sep 25 closing price
Capitalization
15.14M
45 days until earnings call
Interact to see
Advertisement

IDYA vs NERV

Header iconIDYA vs NERV Comparison
Open Charts IDYA vs NERVBanner chart's image
IDEAYA Biosciences
Price$25.69
Change+$0.02 (+0.08%)
Volume$1.67M
Capitalization2.25B
Minerva Neurosciences
Price$2.17
Change-$0.03 (-1.37%)
Volume$17.01K
Capitalization15.14M
IDYA vs NERV Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. NERV commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and NERV is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (IDYA: $25.69 vs. NERV: $2.16)
Brand notoriety: IDYA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 136% vs. NERV: 61%
Market capitalization -- IDYA: $2.25B vs. NERV: $15.14M
IDYA [@Biotechnology] is valued at $2.25B. NERV’s [@Biotechnology] market capitalization is $15.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and NERV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while NERV’s TA Score has 6 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 4 bearish.
  • NERV’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NERV is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -2.02% price change this week, while NERV (@Biotechnology) price change was +5.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.01%. For the same industry, the average monthly price growth was +9.06%, and the average quarterly price growth was +48.80%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

NERV is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.25B) has a higher market cap than NERV($15.1M). IDYA YTD gains are higher at: -0.039 vs. NERV (-2.548). NERV has higher annual earnings (EBITDA): 11.2M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. NERV (15.2M). NERV has less debt than IDYA: NERV (0) vs IDYA (26.6M). IDYA has higher revenues than NERV: IDYA (7M) vs NERV (0).
IDYANERVIDYA / NERV
Capitalization2.25B15.1M14,914%
EBITDA-380.2M11.2M-3,395%
Gain YTD-0.039-2.5482%
P/E RatioN/A1.46-
Revenue7M0-
Total Cash670M15.2M4,408%
Total Debt26.6M0-
FUNDAMENTALS RATINGS
IDYA vs NERV: Fundamental Ratings
IDYA
NERV
OUTLOOK RATING
1..100
8063
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4654
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5049

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (33) in the Biotechnology industry is in the same range as IDYA (61) in the null industry. This means that NERV’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (69) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

IDYA's Price Growth Rating (46) in the null industry is in the same range as NERV (54) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to NERV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYANERV
RSI
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 12 days ago
77%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAMVX32.97N/A
N/A
T. Rowe Price Mid-Cap Value Adv
FBSIX38.98N/A
N/A
Franklin Mutual U.S. Mid Cap Value R6
SMUYX10.10N/A
N/A
SEI Multi-Strategy Alternative Y (SIMT)
PINDX21.84N/A
N/A
Victory Pioneer Disciplined Growth A
LIGNX12.05N/A
N/A
Loomis Sayles International Growth N

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.08%
IMNM - IDYA
60%
Loosely correlated
-9.33%
SYRE - IDYA
58%
Loosely correlated
-8.18%
NRIX - IDYA
58%
Loosely correlated
-4.25%
CGON - IDYA
57%
Loosely correlated
-0.55%
XENE - IDYA
57%
Loosely correlated
-0.19%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DNLI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-1.14%
DNLI - NERV
34%
Loosely correlated
-0.37%
ANAB - NERV
33%
Poorly correlated
-0.45%
IDYA - NERV
32%
Poorly correlated
+0.08%
MLTX - NERV
31%
Poorly correlated
+4.51%
GBIO - NERV
31%
Poorly correlated
-0.69%
More